These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33911570)

  • 1. Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
    March-Rodriguez Á; Bellosillo B; Álvarez-Larrán A; Besses C; Pujol RM; Toll A
    Ann Dermatol; 2019 Apr; 31(2):204-208. PubMed ID: 33911570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
    Rastrelli M; Ferrazzi B; Tropea S; Costa A; Finotto S; Marino D; Campana L; Del Fiore P; Rossi CR; Alaibac M
    In Vivo; 2019; 33(5):1667-1669. PubMed ID: 31471421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
    Vaddi K; Verstovsek S; Kiladjian JJ
    Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera.
    Gambichler T; Stockfleth E; Susok L
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():63-65. PubMed ID: 34855240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
    Aboul-Fettouh N; Nijhawan RI
    JAAD Case Rep; 2018 Jun; 4(5):455-457. PubMed ID: 29984281
    [No Abstract]   [Full Text] [Related]  

  • 6. Unexpected Neurological Symptoms of Ruxolitinib: A Case Report.
    Furia F; Canevini MP; Federici AB; Carraro MC
    J Hematol; 2020 Dec; 9(4):137-139. PubMed ID: 33224394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent
    Hanna RM; Khalid M; El-Nour LA; Selamet U
    Antibiotics (Basel); 2019 Sep; 8(3):. PubMed ID: 31527456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.
    Blechman AB; Cabell CE; Weinberger CH; Duckworth A; Leitenberger JJ; Zwald FO; Russell MA
    J Drugs Dermatol; 2017 May; 16(5):508-511. PubMed ID: 28628689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib.
    Çetinarslan T; Aydoğdu İ; Ermertcan AT
    J Dermatol; 2024 Oct; ():. PubMed ID: 39428662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes.
    Cingam S; Flatow-Trujillo L; Andritsos LA; Arana Yi C
    J Blood Med; 2019; 10():381-390. PubMed ID: 31814788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase inhibitors: jackpot or potluck?
    Pavithran K; Pande SB
    Oncol Rev; 2012 Mar; 6(1):e13. PubMed ID: 25992203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
    Hirano A; Yamasaki M; Saito N; Iwato K; Daido W; Funaishi K; Ishiyama S; Deguchi N; Taniwaki M; Ohashi N
    Respir Med Case Rep; 2017; 22():87-90. PubMed ID: 28721333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib for the Treatment of Essential Thrombocythemia.
    Gunawan A; Harrington P; Garcia-Curto N; McLornan D; Radia D; Harrison C
    Hemasphere; 2018 Aug; 2(4):e56. PubMed ID: 31723782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report.
    Loutsou M; Georgakopoulou VE; Roussakis N; Chadia K; Steiropoulos P
    Cureus; 2024 Jul; 16(7):e63791. PubMed ID: 39100065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.
    Hirai N; Kasahara K; Yoshihara S; Nishimura T; Omori K; Ogawa Y; Ogawa T; Hishiya N; Suzuki Y; Yano H; Yoshikawa M; Mikasa K
    IDCases; 2020; 21():e00892. PubMed ID: 32642438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib.
    Khanna U; Richardson V; Hexner E; Nguyen CV; Elenitsas R; Rosenbach M
    JAAD Case Rep; 2019 Oct; 5(10):895-897. PubMed ID: 31681830
    [No Abstract]   [Full Text] [Related]  

  • 19. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinib.
    Fabiano A; Calzavara-Pinton P; Monari P; Moggio E; Pellacani G; Manganoni AM; Gualdi G
    Br J Dermatol; 2015 Oct; 173(4):1098-9. PubMed ID: 25997466
    [No Abstract]   [Full Text] [Related]  

  • 20. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.